key: cord-0922228-mtdctez5
authors: Hua, Yi; Dai, Xiaowen; Xu, Yuan; Xing, Guomeng; Liu, Haichun; Lu, Tao; Chen, Yadong; Zhang, Yanmin
title: Drug repositioning: Progress and challenges in drug discovery for various diseases
date: 2022-02-28
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2022.114239
sha: ca54b816e48c57ea40821b73082d67c6a0fb1f61
doc_id: 922228
cord_uid: mtdctez5

Compared with traditional de novo drug discovery, drug repurposing has become an attractive drug discovery strategy due to its low-cost and high efficiency. Through a comprehensive analysis of the candidates that have been identified with drug repositioning potentials, it is found that although some drugs do not show obvious advantages in the original indications, they may exert more obvious effects in other diseases. In addition, some drugs have a synergistic effect to exert better clinical efficacy if used in combination. Particularly, it has been confirmed that drug repositioning has benefits and values on the current public health emergency such as the COVID-19 pandemic, which proved the great potential of drug repositioning. In this review, we systematically reviewed a series of representative drugs that have been repositioned for different diseases and illustrated successful cases in each disease. Especially, the mechanism of action for the representative drugs in new indications were explicitly explored for each disease, we hope this review can provide important insights for follow-up research.

Drug discovery and development is an expensive, time-consuming, and risky business. The average 28 Although some of the drugs discussed here appear to be good candidates for further research, 1 it is uncertain whether any of them will succeed as successful therapies for Alzheimer's disease and 2 a more systematic approach is needed to screen approved drugs and analyze epidemiological 3 biological and clinical data to identify new potential candidates for repurposing in Alzheimer's 4 disease. It is also important to consider the optimal stage of the disease for treatment based on the 5 mechanism of action of new indications and thus to determine whether the trial should target early-6 clinical Alzheimer's patients [42] . 7 8 One of the most representative cases of drug repositioning in neurological disease comes from 9 galantamine. Galantamine is a phenanthridine alkaloid isolated from galanthus caucasicus in 10 1947 [43] . After a few years, its structural characteristics were obtained and used for surgery and 11 anesthesia. Galantamine was mainly used as a cholinesterase inhibitor in the 1960s to treat diseases 12 such as polio and muscle atrophy. Because its activity is better than pyridostigmine but weaker than 13 neostigmine, it has not attracted widespread attention [44] . Another reason that hinders the 14 development of galantamine is its extremely low synthesis efficiency as galantamine is more 15 difficult to synthesize than other analogs. Research in the 1990s [45] found that galantamine can 16 types. Surprisingly, a great number of non-oncology drugs can selectively inhibit cancer cell line 1 subsets [59] . Some of these drugs even discovered cancer targets that were not previously 2 involved [59] . Researchers found that the mechanism of action of most anti-cancer drugs is mainly 3 through the replacement of proteins. This study found that some drugs do not only block proteins 4 but instead activate or stabilize protein-protein interactions [59] . 5 6 Colorectal cancer is the second leading cause of cancer death worldwide, mutations in the TP53 7 gene are the leading cause of colorectal cancer [60] . The p53 protein is encoded by the TP53 8 gene[61]. p53 can not only promote the repair and survival of damaged cells but also promote the 9 permanent removal of irreparable damaged cells through apoptosis or autophagy [62] . Therefore, the 10 complex regulation of p53 can prevent tumor incidence and progression [62] .With the development 11 of genomics and screening of existing drugs, it has been discovered that non-oncology drugs have 12

shown anticancer activity [63, 64] . Chlorpromazine (CPZ) ( Table 2) is mainly used to treat 13 psychiatric diseases by blocking postsynaptic dopamine receptors in cortical and limbic areas of 14 brain. Studies have found that the apoptosis of tumor cells induced by CPZ depends on the 15 expression of p53 [61] . Therefore, CPZ offers potential for the treatment of CRC and provides 16 effective research ideas for drug repositioning due to polypharmacology. Dehydroepiandrosterone 17 (DHEA) ( Table 2) is a major C19 steroid produced by the adrenal. It has been reported that DHEA 18 can significantly inhibit 1,2-dimethylhydrazine-induced colon tumors in BALB/c mice [65] in 1984. 19

The mechanism of action for DHEA is to reduce the number of abnormal crypt foci (ACF) induced 20 by azoxymethane (AOM) to achieve the purpose of treatment. The results of acting on different 21 targets should make a wary of side effects. Orlistat (Table 2) Table 2) is a specific inhibitor of pyruvate dehydrogenase kinase 5 (PDK). It increases pyruvate flux into the mitochondria by inhibiting the PDK, promoting glucose 6 oxidation. As early as 1956, Otto Warburg observed that cancer cells inherently depend on 7 glycolysis to produce chemical energy [69] . PDK inhibitors can attenuate the effect of glycolysis to 8 promote the oxidative phosphorylation of mitochondria and inhibit the growth of colorectal cancer 9 cells [70] . This case indicates that repurposing strategy is related to a similar mechanism of action 10 but applies in different diseases settings. Non-hormonal compounds are binding to estrogen 11 receptors that could produce beneficial effects on the skeletal system without adverse effects on 12 other tissues. These compounds were called selective estrogen receptor modulators (SERM). 13 Table 2) is a SERM that the FDA approves to treat and prevent postmenopausal 14 osteoporosis in women. Through research on the prevention of different types of colon cancer, it 15 was discovered that raloxifene may act as an ER-β antagonist to achieve the purpose of preventing 16 colon cancer [71] . The death of patients due to tumor recurrence is also a major obstacle in cancer 17 treatment. A reasonable explanation is that the cells continue to exist and enter the cell cycle after 18 the induced stimulation during the dormant period. Comparison of different tumor cells disclosed 19 that dormant colorectal cancer (CRC) cells are chemo-resistant [72] . Therefore, it is hoped that drugs 20 can interfere with the dormant state to kill cancer cells to prevent cancer recurrence completely. The 21

repositioning strategy is related to mechanisms of action in different diseases settings. to inhibit ovarian cancer. Anti-tumor drug repositioning mainly starts from the research of 6 mechanism. It is hoped that the method of drug repositioning can not only achieve the effect of 7 treating ovarian cancer, but also obtain a certain preventive effect. 8

Ciglitazone decreases differentiation and angiogenesis in human umbilical vein endothelial cells 9

to exert an anti-hyperglycemic effect. Ciglitazone (Table 3) is a highly selective agonist of PPARγ 10 and improves insulin sensitivity. In vivo studies have found that ciglitazone can inhibited glucose 11 uptake in ovarian cancer cells and decreased expression of glucose transporter-1 (GLUT-1)[86]. 12

Based on mechanistic studies, the polypharmacology of ciglitazone is beneficial for drug 13

repurposing. Clofibric Acid (CA) ( properties. Ritonavir (Table 3) , an HIV protease inhibitor, cleaves both structural and functional 23 proteins to inhibit the formation of infectious virions to produce the antiviral effect. When the body's 24 innate immune system is weakened, it increases the risk of solid tumors. Researchers found that 25 ritonavir can inhibit the apoptosis of a variety of tumor cells [89, 90] . Ritonavir inhibits cancer 26 cells from exerting anti-tumor effects by depleting G1 cyclin and mediating G1 cell cycle arrest of 27 ovarian cancer cells [91] . Ritonavir synergistically inhibits AKT to increase the efficacy of cell 28 apoptosis. Therefore, it is recommended that ritonavir be used as an enhancement drug for the 29 treatment of ovarian cancer. The drug repurposing strategy is based on specific mechanism of action for different diseases settings. Inhibiting mevalonate pathway has an inhibitory effect on the growth 1 of ovarian cancer cells, so it is also a novel strategy to consider drugs targeting this pathway for the 2 treatment of ovarian cancer [92] . Alendronate possibly inhibits the mevalonate pathway to inhibit 3 bone resorption for the treatment of osteoporosis. Alendronate (Table 3) the proliferation of cancer cells by regulating a variety of signal pathways. It mainly blocks cell 20 cycle progression and promotes apoptosis by blocking KPNB1 [102] . Besides, ivermectin can also 21 inhibit the growth of ovarian cancer by targeting molecules in the energy metabolism pathway [103] . 22

This evidence is sufficient to prove that ivermectin has great potential for the treatment of ovarian 23

cancer. The case also proved that ivermectin acts on multiple targets pertaining to multiple diseases 24 pathways. 25 Table 3) is the first choice for treating diabetes in clinics by lowering hepatic glucose 26 output, and the discovery that metformin can inhibit the growth of cancer cells in vivo and in vitro 27 has aroused great interest from scientists. Studies have shown that metformin can reduce cancer 28 mortality[104-106]. Many different studies on the mechanism of action of metformin were 29 performed. When cisplatin was used in combination with metformin, as the concentration of metformin increased, the half-maximal inhibitory concentration of cisplatin on the ovarian cancer 1 CP70 cell line decreased significantly. In addition, in an apoptosis experiment of ovarian cancer 2 epithelial cells, it was found that metformin can induce the apoptosis of OVCAR-3 and OVCAR-3 4 cell lines that depend on adenosine phosphate active protease (AMPK) and inhibit cancer cells. 4

Although there are many studies on the anticancer mechanism of metformin, it is still in the 5 experimental stage, and its safety and effectiveness are still to be explored. Mechanism studies 6 proved that the repurpose strategy is based on polypharmacology. 7 

Melanoma is a malignant tumor that develops from melanocytes that originate in the nerve 3 ridge. Melanoma is a very deadly skin cancer that starts in melanocytes. Ultraviolet (UV) light 4 radiation from sunlight and the number of melanocytic nevi is the main environmental risk factors 5 for melanoma skin cancer development [107] . In the past, the main treatment strategies for malignant 6 melanoma were surgery, radiotherapy, and chemotherapy. Nowadays, there are currently some 7 drugs on the market that can be used to treat melanoma, but it is still difficult to treat melanoma 8 because of drug resistance and high metastasis. Through the study of melanoma signaling pathways, 9

it has been found that STAT3 plays an important role, so it is proposed to use STAT3 inhibitors as DSF is combined with copper, it shows that it can inhibit drug resistance-related targets, so DSF is 20 considered to have great development potential. Riluzole (GRM1 blocker) ( Table 4 ) is used to treat 21 amyotrophic lateral sclerosis (ALS) [121] . Early studies have found that ectopic expression of whether the combination drugs can inhibit the spread of melanoma needs further research. Although 10 the mechanism of action is unknown, the drug repurposing strategy is suspected to be related to 11 polypharmacology due to different targets. 12 Table 4 

During the 1950s-1960s, thalidomide was widely used as an antiemetic for pregnant women, 

The current speed of discovery of antibiotics is much lower than the peak period of 1940-6 1960[133] . The main reason is that antimicrobial resistance has weakened the speed of antimicrobial 7 development. Antimicrobial resistance is a serious global problem, new drugs, and novel treatments 8 are urgently needed to improve this situation [134] . As with other drugs, de novo antibacterial 9 discovery is a long and arduous process, which not only requires time and cost but also has very 10 high safety and toxicity risk [135] . Due to its effectiveness, drug repositioning has made substantial 11 progress in the development of alternative drugs for the treatment of bacterial and fungal infections 12 over the past decade. And it has become one of the major strategies for the drug development of 13 pharmaceutical companies. Recent research has found that bithionol, a drug previously used to treat 14 parasitic infections in horses, is being reused to kill antibiotic-resistant bacteria, including 15

Methicillin-resistant Staphylococcus aureus (MRSA), a common hospital-acquired infection. This 16 is a successful case in which scientists are addressing resistance by exploring drug repositioning. The drug repurposing strategy has obvious advantages in the combined treatment of 10 antimicrobial drugs. Pentamidine (Table 5) makes sertraline promising as an antifungal drug. Due to the lack of antibiotics that can be used to 24 treat methicillin-resistant S. aureus (MRSA), an alternative therapy continues to be found. It proved 25 that sertraline acts as SSRI but repurposed for different diseases settings. Aspirin relieves pain and 26 reduces fever mainly due to decreased prostaglandins and TXA2. However, aspirin (Table 5) polypharmacology. Others proved that although aspirin is less effective than ordinary antibiotics, it can exert a synergistic effect as an adjuvant for MRSA [148] . Flupenthixol is a powerful 1 antagonist of both D1 and D2 dopamine receptors [149] . Recently, it is found that flupenthixol 2 reduces the proton pump activity of S. aureus by decreasing the transmembrane potential. Different 3 targets and mechanisms of action indicate that the repurposing strategy is related to 4 polypharmacology. In view of the increasing number of pathogenic organisms with multidrug 5 resistance, combination therapy may prove to be the best option. 6

Thioridazine ( Table 5 ) was a typical antipsychotic drug act on Dopamine D2 and D1 receptor 7 in its early period, and it was stopped using in 2005 due to adverse cardiac reactions [150] . 8

Thioridazine proved to be sensitive to methicillin-sensitive S. aureus (MSSA), Enterococcus, and 9

M. tuberculosis, the mechanism of action is suspect the inhibition of membrane-bound enzymes 10 [151] . Although thioridazine has lost its role in the treatment of psychosis, it still has great potential 11 in antifungals. Different mechanisms of action in different targets indicate that drug repurposing 12 may provide a strategy for developing antimicrobial drugs. Signaling pathways that activate Immunosuppressants often lead to reduced immune function in the treatment of autoimmune 19 diseases, accompanied by fungal infections. Therefore, research on the antifungal activity of 20 immunosuppressants has been increased. Rapamycin (Table 5) Although rapamycin cannot be used as an antibacterial drug in clinical trials, it is still a potential 25 antibacterial drug due to its target. The advantage of this repurposing strategy is combination 26 therapy due to act on different targets. Prochlorperazine mainly works on D2 dopamine receptors 27 and is used for the treatment of anxiety and schizophrenia. In vitro screening shows that 28 prochlorperazine has strong antibacterial activity in Bacillus and Enterobacter [154] . Especially, it 29 was found to reduce the proton motive force of S.aureus by reduction in the transmembrane potential [155] . Prochlorperazine biased towards adjuvants for combined use against multiple fungi 1 in the subsequent development process. Lacidipine (Table 5) is a powerful third-generation calcium 2 channel blocker used to treat hypertension [156] . In 2007, it was found through in vitro screening 3 that the drug has essentially antibacterial effects on S. aureus and V. cholerae [157] . The primary 4 mechanism may be the combination of lacidipine and conventional antibacterial drugs to cause 5 structural modification or enhance its antibacterial effect [157] . The mechanism of antibacterial 6 action of lacidipine needs further study. Nifedipine (Table 5) is L-type calcium channel blocker. 7

In the experiment, it showed promising antibacterial activity against Cryptococcus, Candida and 8

yeast. The compounds screened to have antibacterial effect belong to dihydropyridines, so it is 9 believed that the antibacterial effect is mainly related to its structure. Experimental results show that 10 the antifungal effect of the calcium channel blocker (CCB) involves the regulation of Cch1-Mid 11 calcium channels [158] . Although nifedipine belongs to non-dihydropyridine CCB, it belongs to L-12 type CCB [159] . Mechanism studies suggest that nifedipine repurposes in different disease settings. 13

Zidovudine (Table 5) (Table 5) initially 26 targets estrogen receptor that is prevalent in receptor-positive breast cancers. But the drug also 27 affects neutrophils and produces neutrophil extracellular traps (NETs), a mesh of proteins that kill 28 bacteria. The 'off-target effects' could have critical clinical implications. Another method is to 29 screen based on the specific effective structure of antibacterial drugs to find potential antibacterial drugs. Ejim et al.[166] proposed screening from approved drug libraries, and obtained six non-1 antibacterial drugs, which enhanced the activity of Mexicycline against a reference Pseudomonas 2 aeruginosa strain. Bacterial resistance is accompanied by a gradual decrease in treatment options, 3

and multiple aspects need to be taken to address the issue of global antimicrobial resistance. In short, 4 the combination of drug repositioning of antimicrobials and the rapid development of new drug 5 mechanisms can reduce the abuse of antimicrobials or reduce the constant threat of antimicrobial 6 resistance. It is through different approaches that humans can cope with the challenges posed by 7 antimicrobial resistance. S.aureus, S.epidermidis and Streptococcus pyogenes [169] . Among all topical skin drugs, 3% 8 clioquinol has the strongest antifungal activity. Based on reported researches, it is believed that 9 clioquinol can be a promising formulation in topical epidermal mycosis [167] . It can also be used in 10 combination with systemic antifungal agents to reduce the occurrence of drug resistance and 11 enhance efficacy. It has a broad antifungal spectrum and has moderate to strong activity among 12 common pathogenic fungi. In addition, studies have shown that clioquinol does not exhibit an 13 antibacterial effect by directly binding ergosterol to exhibit plasma membrane instability. Through 14 in-depth study of the mechanism, it is shown that clioquinol can act on the cell wall more effectively 15 than other derivatives to exert antibacterial effects [170] . Therefore, reasonable structural 16 modification can speed up the development of antifungals and enhance the application. 17

Influenza virus infection has become a serious worldwide health problem due to its infectivity. 19

The virus was first discovered in tobacco plants. Researchers Mechanism studies have found that ZIKV infection leads to increased caspase-3 activation, which 13

in turn leads to cell death [174] . Emricasan (Table 6) is the first caspase inhibitor tested in human 14 which is used to protect liver cells from excessive apoptosis. Emricasan exerts antiviral effects by 15 reducing neuronal cell death and inhibiting the activity of caspase-3, which is induced by ZIKV. 16

The repurposing strategy is based on the same target but repurposing for different diseases settings. it is found that MPA shows the most effective antiviral effect on ZIKV [177] . The mechanism of 28 the drug's effect may be due to targeting the ZIKV replication process [177] . In addition, the safety 29 of MPA makes it a potential drug for the treatment of the ZIKA virus. Research studies indicate that the drug repurposing strategy of MPA is related to specific mechanism of action but repurpose 1 for different disease settings. Mefloquine inhibits merozoite invasion and proteins interactions 2 involved with nutrient uptake to exert an antimalarial effect. Mefloquine ( Table 6) Different from the wet experimental screening method, mefloquine was obtained by calculating the 5 electrostatic potential map of the compound through molecular modeling, and the antiviral activity 6 was tested by experiment [178] . Since this drug has shown adverse events of anxiety or 7 hallucinations in clinical trials, mefloquine needs to be tested in vivo to further evaluate its safety. 8

Also, its detailed mechanism of action remains to be further studied. Suramin ( Table 6) The drug repurposing strategy with specific mechanism but repurpose for different diseases settings. 19

Sofosbuvir is well tolerated and safe in its original pharmacological effects, and these advantages 20 can support its development as an anti-ZIKV drug. Favipiravir (T-705) ( Table 6) Table 6 ) is a type of glycoside compound that 8

can enhance myocardial contractility. It inhibits the Na + -K + -ATPase on tissues to increase 9 intracellular Ca 2+ concentrations to promote inotropy and bradycardia [185] . GC has recently been 10 shown to have anti-cancer and antiviral activities [186] . As a typical cardiac glycoside compound, 11 digoxigenin can effectively inhibit HCMV at a concentration of nanomolar level [187] . Studies have 12

found that cardiac glycosides may inhibit HCMV replication by regulating transcription and 13 translation. Therefore, it is recommended to explore its significance on the combination treatment 14 in subsequent development. Different mechanisms of action on different targets lead to drug 15 repurposing strategies. Emetine (Table 6) emetine as a potential candidate drug for anti-HCMV is that it adopts a new type of host-dependent 24 antiviral mechanism and has higher safety, whether it is a single drug or a combination drug. 25

Nitazoxanide (Table 6) initially acts on pyruvate-flavodoxin oxidoreductase for the treatment of 26 diseases caused by other protozoa or helminths. It was later proved that it has effective activity 27 against a variety of RNA and DNA viruses, including influenza and a variety of viruses [189] . 28

Nitazoxanide has been regarded as a broad-spectrum antiviral drug due to inhibit the replication of 29 several RNA and DNA viruses [190] . The drug repurposing strategy is on the basis of specific mechanism but repurpose for different diseases settings. Manidipine ( Table 6 ) is used as a calcium 1 channel blocker for the treatment of hypertension. Human cytomegalovirus (HCMV) is a 2 widespread herpes virus, and congenital HCMV infection is one of the causes of fetal death [191] . 3

The IE2 protein of HCMV is an important regulator of viral and host cell gene expression [192] . 4

Studies have shown that manidipine explicitly inhibits the replication of HCMV by interfering with 5 the IE2-dependent activation of the viral E gene [193] . Mechanisms studies demonstrated that the 6 repurposing strategy for manidipine is related to polypharmacology. Ferroquine (FQ) ( Table 6) is 7 used for treating malaria may due to inhibit β-hematin formation. Recently, it is investigated as a 8

novel HCV inhibitor. The study of its antiviral mechanism found that the entry stage of HCV is an 9 attractive stage for virus intervention [194] . Ferroquine not only inhibits the binding of HCV into 10 target cells, but also inhibits RNA replication, and finally exhibits antiviral activity independent of 11 genotype. In addition to single-agent antiviral studies, the combination of FQ and interferon (IFN) 12 or HCV NS3/4A protease inhibitor also showed a synergistic antiviral effect. The different 13 mechanism of action for FQ provide drug repurposing strategy. Ayami Sato et al. found that 14 suberoylanilide hydroxamic acid (SAHA) ( Table 6) has become a public emergency of international concern. The main clinical symptoms of confirmed 6 cases are fever, cough, dyspnea, and vomiting [199] . The receptors of SARS-CoV-2 and SARS-CoV 7 are both angiotensin-converting enzyme 2 (ACE2), and mucosal cells contain many ACE2 receptors. 8

The virus could continue infecting new hosts by generating numerous copies of its genome and 9 packaging them into virions. Finally, the capsid and RNA are composed to generate new virus 10 particles and released out of the cell to infect new cells [197] . COVID-19 is a serious respiratory 11 disease. Since there are no drugs to treat the virus, drug repurposing is an existing effective response 12 strategy. Zhou et al. [202] used web-based drug repositioning methods to quantify the interaction between 19 drugs and targets, and identified 16 potential anti-human coronaviruses (SARS-CoV and SARS-1

CoV-2) drugs. Table 7 summarizes drugs screened by different methods or for different target 2 proteins as potential drugs for further research. 3

Remdesivir is a nucleoside analog with antiviral activity and the first drug approved by the 4 FDA for the treatment of COVID-19. Previous reports have shown that remdesivir has a variety of 5 antiviral activities in vitro [203] [204] [205] , including SARS-CoV [206] and MERS-CoV [207] . 6

Remdesivir is a diastereomeric monophosphate phosphoramidate prodrug that inhibits viral RNA learning predicts that poly ADP-ribose polymerase 1 (PARP1) inhibitor CVL218 is an effective 20 drug against coronavirus and has been experimentally verified in vitro [209] . Researchers speculated 21 that CVL218 might target the N-terminal domain of SARS-CoV-2 to impede viral replication. They inhibiting virus replication [209] . This is also the basic research that PJ-34 is considered to be an 29 effective antiviral drug [212] . The method of describing the interaction between drugs and viral targets based on the knowledge map also confirmed that PJ-34 might have anti-SARS-CoV-2 1 activity. But further clinical verification is needed. The repurposing strategy of CVL218 and PJ34 2 is based on specific mechanisms of action but repurposes for different diseases settings. One of the representative cases of drug repositioning in antiviral is the use of Chloroquine 2 (CQ) to treat ZIKA. CQ is a commonly used anti-malarial drug, which has important clinical 3 significance. Besides, CQ is also used to treat rheumatoid arthritis and other autoimmune diseases. 4

It has been proven that CQ can reduce ZIKV-related morbidity and mortality [232] . One of the main 5 challenges of ZIKV is congenital fetal malformations caused by an infection in pregnant women. 6 CQ has a long and successful history, and there is no clear evidence that it can cause fetal harm 7 when used to prevent malaria [233] . Therefore, CQ is recommended for the prevention and treatment Furthermore, studies have shown that CQ can inhibit SARS CoV-2 replication in Vitro, but it 13

has not shown obvious advantages in vivo. It is currently proposed that the antiviral mode of action 14 may intervene life cycle of the virus. Another suggested mechanism is to inhibit quinone reductase 15 2[235], which is necessary for sialic acid, while coronaviruses are abundant in sialic acid [236] . 16

Recent antiviral studies have shown that CQ interferes with the glycosylation process of the cellular 1 receptor ACE2 to inhibit SARS CoV-2 from entering cells [237] . It is necessary to pay attention to 2 the G6PD activity in the blood of patients in clinical trials. The use of CQ in patients with G6PD 3 deficiency may bring high-risk adverse reactions[238]. 4

Drug repositioning has become a successful drug discovery strategy due to reduced costs and 6 faster approval procedures. Many successful examples have also shown the great potential of this 7 method in practice. Drug repositioning has multiple advantages, including safety, money-saving 8 market potential advantages, and return on investment potential. It is known that the safety of 9 existing drugs reduces the risk of drug discovery, and this advantage fetches up shortcomings of 10 drug development due to safety failures. As the cost of repositioning is much lower than the de novo 11 drug development, it provides a new strategy for non-profit organizations and academic centers. 12

The repositioned drug Thalomid and its derivatives have brought more than 2.8 billion U.S. dollars simultaneously, which can help us to identify potential candidates and greatly improve screening 20 efficacy by computational methods. 21

The rapid growth of disease and drug-related data sets in recent years has also brought rapid 22 development to computational drug repositioning, especially structure-based drug repositioning. 23

Strategies like machine learning and knowledge-based mapping such as network pharmacology can 24 more accurately analyze the internal relationship between drugs and targets, thereby obtaining more 25 meaningful information. Considering the sudden global major public health event such as COVID-26 19, computational drug repositioning is one of the most feasible strategies. To better understand the 27 role of different methods in drug repositioning, and provide methodological guidance for future 28 public health emergencies, we recommend combining experimental and computational approaches 29 to improve the efficiency of drug repositioning. In this article, we reviewed new mechanisms of 1 action for drugs on common diseases including neurological diseases, cancer, microbial, and virus 2 infections. The opportunities for drug repositioning are of great potential. Although different drugs 3 adopt different identification approaches for repositioning, most of them stay before phase II clinical 4 trial, which is still far away from markets. A better way is to combine multiple approaches both 5 computationally and experimentally for different situations and exploring specific mechanisms, 6

providing novel insights and helping identify candidates for new treatment. 

Deconstructing the Drug Development Process: The New Face of Innovation, Clinical elderly Japanese population: the Hisayama Study

15-year longitudinal study of blood pressure and dementia

Drug 6 repositioning for Alzheimer's disease

Do Cancer Drugs Counteract

Alzheimer's Disease

Functional analyses of major cancer-related signaling pathways 11 in Alzheimer's disease etiology

Formation of covalent complexes between human O 6 alkyltransferase and 14 BCNU-treated defined length synthetic oligodeoxynucleotides

-chloroethyl)-1-nitrosourea (BCNU)

Striking 19 reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of 20 carmustine

Bexarotene: a promising anticancer agent

Slow-cycling therapy-resistant cancer cells, Stem Cells & 18

Effects of the antifungal agents on oxidative 20 drug metabolism

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer

Ivermectin, a potential anticancer drug derived from an 11 antiparasitic drug

Increased Cancer-Related Mortality for 13

Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

Metformin 15 Associated With Lower Cancer Mortality in Type 2 Diabetes

New Users of Metformin Are at Low

Cutaneous melanoma: From pathogenesis to therapy (Review)

Organogold drug Auranofin exhibits anti-melanogenic activity in B16F10 3 and MNT-1 melanoma cells

Spontaneous regression of breast cancer

Disulfiram induces copper-dependent 6 stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma

Disulfiram induces 9 apoptosis in human melanoma cells: a redox-related process

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron 12 disease (MND)

Metabotropic glutamate receptor 1 14 and glutamate signaling in human melanoma

A phase II trial of riluzole, an antagonist of 16 metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

Leflunomide Aventis Pharma

Multiple inhibitor analysis of the brequinar 21 and leflunomide binding sites on human dihydroorotate dehydrogenase

Leflunomide: efficacy and safety in clinical trials 24 for the treatment of rheumatoid arthritis

DHODH modulates transcriptional elongation in the neural crest and melanoma

Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic 30 Drug for Melanoma Treatment

Molecular mechanisms of novel therapeutic approaches for multiple 32 myeloma

Antitumor activity of thalidomide in refractory multiple myeloma

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial 40 growth factor secretion: therapeutic applications

Therapeutic effects of thalidomide in hematologic disorders: a review, 42 Frontiers of Medicine

Wildcatters welcome: the need for new antimicrobial agents

Discovery and development of new antibacterial drugs: 2 learning from experience?

Thioridazine: resurrection as an antimicrobial agent?

Function and regulation in MAPK signaling pathways: Lessons learned from 4 the yeast Saccharomyces cerevisiae

vitro interactions between antifungals and 6 immunosuppressive drugs against zygomycetes

Antibacterial property of the 9 antipsychotic agent prochlorperazine, and its synergism with methdilazine

Multidrug Efflux Pump Activity in Staphylococcus aureus

The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in 16 the apoE-deficient mouse

Studies on the antimicrobial 18 potential of the cardiovascular drug lacidipine

Repurposing drugs to fast-track therapeutic 20 agents for the treatment of cryptococcosis

Novel cell-based 22 in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus 23 neoformans in macrophages

The Monomesylates of 1-(2'-Deoxy-β-D-25 lyxofuranosyl)thymine1,2

Novel polymyxin combination with the antiretroviral zidovudine 28 exerts synergistic killing against NDM-producing multidrug-resistant Klebsiella pneumoniae

Nucleoside analogues as antibacterial agents

Repurposing Non-Antimicrobial Drugs and Clinical 33 Molecules to Treat Bacterial Infections

Antifungal Drug Discovery: Something Old and Something 37 New

Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy

Clioquinol, an alternative antimicrobial agent against 42 common pathogenic microbe

Clioquinol: Review of its Mechanisms of Action and Clinical Uses in

Antimicrobial activity of topical skin 2 pharmaceuticals -an in vitro study

New insights into the mechanism of antifungal action of 8-5 hydroxyquinolines

Can you teach old drugs new tricks?

A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug 15 repurposing screen

Zika Virus Infects Human Cortical Neural 18 Progenitors and Attenuates Their Growth

Mycophenolic Acid Inhibits Dengue Virus Infection by

Preventing Replication of Viral RNA

Mechanisms of action of mycophenolate mofetil

The clinically approved 35 antiviral drug sofosbuvir inhibits Zika virus replication

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA 37 polymerase

Antiviral efficacy of favipiravir 39 against Ebola virus: A translational study in cynomolgus macaques

Anticancer and Antiviral Properties of 2 Cardiac Glycosides: A Review to Explore the Mechanism of Actions

Human Cytomegalovirus Inhibition 5 by Cardiac Glycosides: Evidence for Involvement of the hERG Gene

Efficacy and Mechanism of Action 8 of Low Dose Emetine against Human Cytomegalovirus

Nitazoxanide: A first-in-class broad-spectrum antiviral agent

Manifestations of Human Cytomegalovirus Infection: Proposed Mechanisms of Acute and 14 Chronic Disease

Human cytomegalovirus 86-kilodalton IE2 protein blocks cell cycle 16 progression in G(1)

Repurposing the clinically 18 approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human 19 cytomegalovirus targeting the Immediate-Early 2 (IE2) protein

New advances in the molecular biology of hepatitis C virus 21 infection: towards the identification of new treatment targets

Suppressive effect of the histone deacetylase inhibitor 24 suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication

Effects of SAHA on proliferation and apoptosis of 27 hepatocellular carcinoma cells and hepatitis B virus replication

Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2, Cureus

Severe Acute Respiratory Syndrome Coronavirus

CoV-2) and Coronavirus Disease-2019 (COVID-19): A Review

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-36 Infected Pneumonia in Wuhan, China

Etravirine against main protease and RNA-dependent RNA polymerase of 39

-2: A molecular docking and drug repurposing approach

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) 42 structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

Network-based drug repurposing for novel 1 coronavirus 2019-nCoV/SARS-CoV-2

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic 9 coronaviruses

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase 13 and the Proofreading Exoribonuclease, mBio

Structural Basis for the Identification 31 of the N-Terminal Domain of Coronavirus Nucleocapsid Protein as an Antiviral Target

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and 35 Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates 36 in Healthy Subjects

Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19

A search for medications to treat COVID-19 via in silico molecular docking 40 models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the

SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface, in, ChemRxiv

Effect of a novel antiallergic drug, pemirolast, on 6 activation of rat peritoneal mast cells: inhibition of exocytotic response and membrane phospholipid 7 turnover

Mechanisms of action of isoniazid

Evaluation of bitter masking 11 flavanones from Herba Santa (Eriodictyon californicum (H. and A.) Torr., Hydrophyllaceae)

Novel coronavirus treatment with ribavirin: 14 Groundwork for an evaluation concerning COVID-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of 16 patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance, Cold Spring Harb 20

Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola 23

Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory 24

Syndrome Coronavirus (SARS-CoV) *

Fighting viruses with antibiotics: an overlooked path

Teicoplanin potently blocks the cell entry of 2019-nCoV

The role of 31 teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 32 patients (Tei-COVID study)

Nelfinavir inhibits replication of severe 34 acute respiratory syndrome coronavirus 2 in vitro

ChemRxiv, 2020. 37 [231] Multidrug treatment with nelfinavir and cepharanthine against COVID-19

FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital 40 Microcephaly in Mice

Safety of chloroquine in chemosuppression of malaria during pregnancy

Structural basis for human coronavirus attachment to sialic acid receptors

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked 11 by a clinically proven protease inhibitor

The friendly use of chloroquine in the COVID-19 disease: 13 a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the